Chloroquine Online |
|
How and where to order Chloroquine Phosphate (Aralen) 250 mg, 500 mg tablets or capsules online on YMCA Liberia website:
Indications and usage: Aralen (Chloroquine Phosphate) is indicated for the: Aralen does not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of use in malaria: Dosage and administration: The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base. Each 500 mg tablet of Aralen contains the equivalent of 300 mg chloroquine base. In infants and children the dosage is preferably calculated by body weight. Dosage forms and strengths: Aralen (Chloroquine Phosphate) tablets for oral use: 250 mg and 500 mg. Overdosage: Signs and symptoms: Chloroquine is very rapidly and completely absorbed after ingestion. Toxic doses of chloroquine can be fatal. As little as 1 g may be fatal in children. Toxic symptoms can occur within minutes. The symptoms of overdosage may include nausea, vomiting, headache, drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm and conduction disorders including QT prolongation, torsades de pointes, ventricular tachycardia and ventricular fibrillation, followed by sudden potentially fatal respiratory and cardiac arrest. Immediate medical attention is required, as these effects may appear shortly after the overdose. Cases of extrapyramidal disorders have also been reported in the context of chloroquine overdose. Treatment Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis or gastric lavage followed by treatment with activated charcoal. Chloroquine (Aralen) overdose is a life-threatening emergency and should be managed with cardio-respiratory and hemodynamic support, monitoring of potassium along with management of arrhythmias and convulsions, as necessary. A patient who survives the acute phase and is asymptomatic should be closely observed until all clinical features of toxicity resolve. Contraindications: Warnings and precautions: Side effects, adverse reactions: The most common adverse reactions have been identified during post-approval use of chloroquine or other 4-aminoqunoline compounds: maculopathy and macular degeneration, urticaria, nerve type deafness; tinnitus, sensorimotor disorders, hepatitis, increased liver enzymes, anorexia, nausea, vomiting, diarrhea, abdominal cramps, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pancytopenia, aplastic anemia, reversible agranulocytosis, thrombocytopenia, neutropenia, convulsions, mild and transient headache, polyneuropathy, psychosis, delirium, anxiety, agitation, insomnia, confusion, hallucinations, personality changes, depression, hypotension, electrocardiographic changes. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. To report suspected adverse reactions of chloroquine phosphate pills, contact Sanofi pharmaceutical company or your local FDA. Drug interactions: Related medications: Use in specific populations: Pregnancy Usage of chloroquine during pregnancy should be avoided except in the prophylaxis or treatment of malaria when the benefit outweighs the potential risk to the fetus. Radioactively tagged chloroquine administered intravenously to pregnant pigmented CBA mice passed rapidly across the placenta and accumulated selectively in the melanin structures of the fetal eyes. It was retained in the ocular tissues for five months after the drug had been eliminated from the rest of the body. There are no adequate and well-controlled studies evaluating the safety and efficacy of chloroquine in pregnant women. Nursing mothers Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother. The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk was investigated in eleven lactating mothers following a single oral dose of chloroquine (600 mg base). The maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate chemoprophylaxis for the infant is required. Geriatric use Clinical studies of Aralen did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. How to store: Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer required. This will help to protect the environment. Here is a list of popular medications containing chloroquine as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|